Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024. In the quarter to June 2026, revenue grew 10.6%, EPS grew 25.0% and free cash flow grew 557.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

62.11 0.72 −1.15%
Market cap
$15.6B
P/E
18.8×
Fwd P/E
16.7×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 7 7 8

+8 more TTM periods

ROE
44.39% 40.99% 35.53% 30.56%
ROA
33.28% 30.69% 27.02% 23.44%
ROIC
60.45% 50.53% 49.46% 42.67%
Return on Tangible Assets
87.68% 89.31% 68.85% 59.82%
Average Days of Receivables
48.28 50.54 45.14 49.41
Free Cash Flow per Share
4.62 3.50 3.11 2.77
Free Cash Flow
1,158.19 905.17 844.34 744.27
Other line items

Show all line items

Columns are period end dates